TREATMENT OF ADVANCED RENAL-CELL CARCINOMA USING REGIONAL ARTERIAL ADMINISTRATION OF LYMPHOKINE-ACTIVATED KILLER-CELLS IN COMBINATION WITH LOW-DOSES OF RIL-2

被引：13

作者：

HAYAKAWA, M

HATANO, T

OGAWA, Y

GAKIYA, M

OGURA, H

OSAWA, A

机构：

[1] Department of Urology, School of Medicine, University of Ryukyus, Okinawa

来源：

UROLOGIA INTERNATIONALIS | 1994年 / 53卷 / 03期

关键词：

LYMPHOKINE-ACTIVATED KILLER; ARTERIAL ADMINISTRATION; RENAL CELL CARCINOMA;

D O I：

10.1159/000282651

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

We investigated the usefullness and problems of arterial administration of lymphokine activated killer (LAK) cells in combination with systemic IL-2 in the treatment of metastatic renal cell carcinoma (RCC). Ten nephrectomized patients with extrapulmonary and/or nonresectable metastases were treated with arterial infusions of LAK cells and systemic rIL-2 (5 x 10(5) IU twice a day) for 1-12 weeks. Leukapheresis was carried out once or twice a week, and two LAK cell populations generated from two gravity subtypes of peripheral blood lymphocytes were administered separately. Five of 15 metastases treated showed appreciable regression of metastatic sites including bone, muscle and lymph nodes. Two of 15 showed a minor response. Local pain due to metastasis was relieved or disappeared in 6 patients. There was no correlation between the response of the patients and the number of LAK cells used. The 24- and 56-month survival rate was 50 and 25%, respectively. No serious side effects were experienced during treatment. We conclude that regional arterial administration of LAK cells in combination with a low dose of IL-2 is worthwhile as an alternative treatment modality to conventional therapy for a selected group of patients with advanced RCC.

引用

页码：117 / 124

页数：8

共 17 条

[1] Rosenberg S.A., Lotze M.T., Muul L.M., Leitman S., Chang A.E., Ettighausen S.E., Matory Y.L., Skibber J.M., Shiloni E., Vetto J.T., Seipp C.A., Simpson C., Reichert C.M., Observation on the systemic administration of autologuous lvmphokinc-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer, N Engl J Med, 313, pp. 1485-1492, (1985)
[2] Rosenberg S.A., Lotze M.T., Mull L.M., Chang A.E., Avis E.P., Leitman S., Lineham W.M., Robertson C.N., Lee R.E., Rubin J.T., Seipp C.A., Simpson C.G., White D.E., A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone, N Engl J Med, 316, pp. 889-897, (1987)
[3] Fisher R.I., Coltman C.A., Doroshow J.H., Rayner A.A., Hawkins M.J., Mier J.W., Wiernik K., McMannis J.D., Weiss G.R., Margolin K.A., Gemlo B.T., Hoth D.F., Parkinson D.R., Paietta E., Metastatic renal cancer cell treated with interleukin-2 and lymphokine-activated killer cells, Ann Intern Med, 108, pp. 518-523, (1988)
[4] Blay J.-Y., Favrot M.C., Negeier S., Combaret V., Combarct V., Chouaib S., Mercatello A., Kaemmerlen P., Franks C.R., Philip T., Correlation between clinical response to interleukin 2 therapy and sustained production of tumor necrosis factor, Cancer Res, 50, pp. 2371-2374, (1990)
[5] Koretz M.J., Lawson D.H., York R.M., Graham S.D., Murray D.R., Gillespie T.M., Levitt D., Sell (CM: Randomized study of interleukin 2 (IL-2) alone vs. IL-2 plus lymphokine-activated killer cells for treatment of melanoma and renal cell cancer, Arch Surg, 126, pp. 898-903, (1991)
[6] Grimm F.A., Mazumder A., Zhang H.Z., Rosenberg S.A., Lymphokine activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin-2-activated autologous human peripheral blood lymphocytes, J Expmed, 155, pp. 1823-1841, (1982)
[7] Lotze M.T., Rosenberg S.A., Results of clinical trials with the administration of interleukin 2 and adoptive immunotherapy with activated cells in patients with cancer, Immunobiology, 172, pp. 420-437, (1986)
[8] Rosenberg S.A., Lotze M.T., Muul L.M., Chang A.E., Avis F.P., Leitman S., Linehan W.M., Cn R., Lee R.F., Rubin J.T., Seipp C.A., Simpson C.G., White D.E., A progress report on the treatment of 157 patients with advanced cancer using lymphokinc 2 alone, N Engl J Med, 316, pp. 889-897, (1987)
[9] Timonen T., Saksela E., Isolation of human NK cells by density gradient centrifugation, J Immunol Methods, 36, pp. 285-291, (1980)
[10] Fogh J., Tremps G., New human tumor lines, Human Tumor Cells in Vitro, (1975)

← 1 2 →